Kura Oncology receives $30M milestone from Kyowa Kirin for first patient dosed in Phase 3 ziftomenib trial

Kura Oncology, Inc.

$30M milestone payment triggered by first patient dosed in KOMET-017 Phase 3 registrational trials.
Trials evaluate ziftomenib in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.
KOMET-017 consists of two global, randomized, double-blind, placebo-controlled Phase 3 studies.
Payment received under Collaboration and License Agreement with Kyowa Kirin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.